|
postal address
|
IAO_0000422 |
|
|
Phase III Trial
|
NCIT_C15602 |
|
|
Phase IV Trial
|
NCIT_C15603 |
|
|
physical object quality
|
PATO_0001241 |
|
|
behavioral intervention
|
OPMI_0000376 |
|
|
plan specification
|
IAO_0000104 |
|
|
clinical trial sponsor role
|
CTO_0000110 |
|
|
sponsor role
|
OBI_0000243 |
|
|
placebo medical intervention
|
CTO_0000103 |
|
|
enrolled patient
|
CTO_0000102 |
|
|
human subject
|
OPMI_0000381 |
|
|
healthy enrollee
|
CTO_0000101 |
|
|
clinical trial participant
|
CTO_0000100 |
|
|
investigational molecular entity administration
|
CTO_0000107 |
|
|
secondary outcome measurement datum
|
CTO_0000106 |
|
|
primary outcome measurement datum
|
CTO_0000105 |
|
|
drug clinical trial
|
CTO_0000109 |
|
|
Homo sapiens
|
NCBITaxon_9606 |
|
|
investigational molecular entity
|
CTO_0000108 |
|
|
facility contact
|
OPMI_0000384 |
|
